*RINVOQ® is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease.1
If you are still experiencing Crohn’s disease symptoms with your current treatment, there may be uncontrolled inflammation in the gastrointestinal (GI) tract.2
With just one tablet daily, RINVOQ® may help.1,3
Not all medicines are for all patients. Speak to your doctor and see the safety information here for more details.
A once-daily pill for moderate to severe Crohn’s disease1,3
How Crohn’s disease can affect someone can change over time and be different from day-to-day. Many people living with Crohn’s disease keep experiencing flare-ups (more severe symptoms), which can occur between periods of remission (no symptoms) and can be unpredictable.2
RINVOQ® is a once-daily tablet used to treat different autoimmune conditions, including adults with moderate to severe active Crohn’s disease.1,3
How can RINVOQ® help me?1,3,4
RINVOQ® works to reduce the inflammation that can lead to sCrohn’s disease symptoms.
By specifically targeting the inflammatory pathway that contributes to the intestinal symptoms in Crohn’s disease, RINVOQ® may help to improve:
- Abdominal pain
- The need to rush to the toilet (bowel urgency)
- The number of times you go to the toilet (bowel frequency)
You shouldn't have to choose between relief that's fast and relief that lasts*
*In clinical studies,† more patients on RINVOQ® than placebo achieved a clinical response at Week 2 and clinical remission at Week 4 and also achieved clinical remission and endoscopic response at Week 12, sustained at Week 52.‡3,4
†The efficacy and safety of RINVOQ® were evaluated in adult patients with moderately to severely active Crohn’s disease in three multicentre, doubleblind, placebo-controlled Phase 3 clinical studies that included two induction studies involving over 1000 patients, CD-1 and CD-2, followed by a 52- week maintenance treatment and long-term extension study with 502 patients, CD-3.§3,4
Collectively, these trials support that, compared to placebo, a greater percentage of patients who received RINVOQ® achieved:3,4
- Rapid symptom relief, including less abdominal pain and fewer bowel movements, in as early as 2 weeks^
- Early remission without steroids at Week 12 and lasting steroid-free remission at 1 year¶
- Visibly reduced damage of the intestinal lining‖
‡Clinical response was defined as a ≥60% decrease in average daily very soft or liquid stool frequency (SF) and/or ≥35% decrease in average daily abdominal pain score (APS) from baseline. Clinical remission was defined as average daily SF ≤2.8 and APS ≤1.0 and neither greater than baseline. Endoscopic response was defined as a decrease in the Simple Endoscopic Score for CD (SES-CD) of >50% from baseline of the induction trial (or for patients with an SES-CD of 4 at baseline, a decrease of ≥2 points from baseline).3,4
§Enrolled patients were 18 to 75 years of age with moderately to severely active CD defined as an average daily very soft or liquid SF ≥4 and/or average daily APS ≥2, and a centrally-reviewed SES-CD of ≥6, or ≥4 for isolated ileal disease, excluding the narrowing component. In CD-1 and CD-2, 1021 patients (495 and 526, respectively) were randomised to once daily RINVOQ® 45 mg or placebo for 12 weeks with a 2:1 treatment allocation ratio. In CD-1, all patients had an inadequate response or were intolerant to treatment with one or more biologic therapies (prior biologic failure). Of these patients, 61% (301/495) had inadequate response or were intolerant to two or more biologic therapies. In CD-2, 45% (239/526) patients had an inadequate response or were intolerant to treatment with one or more biologic therapies (prior biologic failure), and 55% (287/526) had an inadequate response or were intolerant to treatment with conventional therapies but not to biologic therapy (without prior biologic failure). At baseline in CD-1 and CD-2, 34% and 36% of patients received corticosteroids and initiated a taper regimen starting at Week 4, 7% and 3% of patients received immunomodulators, and 15% and 25% of patients received aminosalicylates. The co-primary endpoints were clinical remission and endoscopic response at Week 12 for CD-1 and CD-2, and at Week 52 for CD-3.3,4
^Symptom relief was assessed as clinical response (defined above) at Week 2 and Week 12.3,4
¶Steroid-free remission was assessed as clinical remission (defined above) and discontinuation of steroid treatment at Week 12 and Week 52 among patients on steroids at baseline.3,4
‖Visibly reduced intestinal damage was based on endoscopy at Week 12 and Week 52 and assessed as endoscopic response (defined above).3,4
RINVOQ® Dosing for Crohn’s disease1,3
To Start
The recommended starting dose for RINVOQ® is 45 mg once a day for 12 weeks.
Maintenance Dose
After 12 weeks, the recommended maintenance dose is 15 mg. In certain cases, your doctor may consider a maintenance dose of 30 mg instead.
Your doctor will prescribe the dose that’s right for you: speak to your doctor and see the safety information here for details on the special dosing considerations with RINVOQ®.
RINVOQ® can be taken with or without food. Avoid food or drink containing grapefruit.
Do not split, crush, or chew the pill.
Inflammatory conditions are chronic conditions, so to help control your symptoms, RINVOQ® should be taken exactly as prescribed by your doctor.
RINVOQ® for Crohn’s Disease
in New Zealand
RINVOQ® is only available with a prescription, so if you are still experiencing symptoms of CD despite your current treatment, consult your gastroenterologist to see if RINVOQ® is right for you.
RINVOQ® is not funded for Crohn’s disease, and you will need to pay the full cost of this medicine if prescribed for these conditions. Usual doctor's consultation fees and pharmacy prescription charges will be payable by you.